🇺🇸 FDA
Pipeline program

Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.

221672

Phase 3 small_molecule active

Quick answer

Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes. for Lung Diseases, Interstitial is a Phase 3 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline Biologicals S.A.
Indication
Lung Diseases, Interstitial
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials